Gold standard HCC screening in patients with cirrhosis more cost-effective than real-life monitoring

Prevention of Multiple Sclerosis
February 10, 2017
Can Big Data Help Cancer Patients Avoid ER Visits?
February 13, 2017
Show all

Gold standard HCC screening in patients with cirrhosis more cost-effective than real-life monitoring

How should people with cirrhosis be monitored?

Gold standard monitoring for hepatocellular carcinoma in patients with cirrhosis, as recommended by guidelines, was more cost-effective and beneficial to patients compared with real-life monitoring, according to the results of a simulation study.

“Compared with ‘real life’ monitoring, following the guidelines for screening — which recommends biannual ultrasound — increased life expectancy by an average of 5 months and was cost-effective at $1,754 per additional life year gained with French costs and at $32,415 per additional life year gained with U.S. costs,” according to a press release.

“The large difference between French and U.S. costs was explained by the 4- to 10-fold difference in unit costs for surveillance — clinic visits, tests — and for first-line curative treatments,” Isabelle Durand-Zaleski, MD, PhD, of the Jean Verdier Hospital, University of Paris, said in the press release.

Durand-Zaleski and colleagues used data from the CIRVIR and CHANGH cohorts to develop a Markov model for simulating a population of patients with compensated cirrhosis, and compared incidence, survival and costs associated with cirrhosis and HCC between gold standard and real-life monitoring over a 10-year period. Cost analyses were performed using French and U.S. health care perspectives.

Over the 10-year period, 37% of patients in the gold standard group were diagnosed with liver cancer vs. 34% in the real-life group, and overall survival was 76% with gold standard monitoring and 67% for real-life monitoring.

Read full article: Gold standard HCC screening in patients with cirrhosis more cost-effective than real-life monitoring

Read Full Article: Gold standard HCC screening in patients with cirrhosis more cost-effective than real-life monitoring

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.